Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux [cetuximab] And CHemotherapy [carboplatin + fluorouracil] for unresectable carcinomas of head and neck

Trial Profile

Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux [cetuximab] And CHemotherapy [carboplatin + fluorouracil] for unresectable carcinomas of head and neck

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Carboplatin; Cetuximab; Fluorouracil
  • Indications Head and neck cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms REACH
  • Most Recent Events

    • 22 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top